

W. Lloyd Clark, MD

Business

Palmetto Retina Center, LLC
124 Sunset Court
West Columbia, South Carolina 29169
(803) 931-0077
Fax: (803) 931-0076
Email: lclark@palmettoretina.com

Residence

5036 Wittering Drive
Columbia, South Carolina 29206
(803) 787-7991

Academic Appointment

2014-present **Assistant Clinical Professor of Ophthalmology**
University of South Carolina School of Medicine
Columbia, South Carolina

Licensure

2000 **South Carolina Board of Medical Examiners #21749**
1999 **State Medical Board of Ohio #35-07-6287-C**
1996 **North Carolina Medical Board #96-01270**

Certification

2001 **Diplomate, American Board of Ophthalmology**
2011 **Maintenance of Certification, American Board of Ophthalmology**

Professional Experience

2004-present **Palmetto Retina Center, LLC**
West Columbia, South Carolina
Vitreoretinal Diseases and Surgery

2000-2003 **Columbia Eye Clinic, P.A.**
Columbia, South Carolina
Vitreoretinal Diseases and Surgery

Post Graduate Training

1999-2000 **Cole Eye Institute, The Cleveland Clinic Foundation**
Cleveland, Ohio
Fellowship, Vitreoretinal Diseases and Surgery

1996-1999 **Bascom Palmer Eye Institute, University of Miami School of Medicine**
Miami, Florida
Residency, Department of Ophthalmology

1995-1996 **University of North Carolina School of Medicine**
Chapel Hill, North Carolina
Internship, Department of Medicine

Education

- 1991-1995 **University of North Carolina School of Medicine**
Chapel Hill, North Carolina
Doctor of Medicine with Honors
- 1987-1991 **Duke University**
Durham, North Carolina
Bachelor of Arts, English

Honors

- 1995 Alpha Omega Alpha Medical Honor Society
- 1993-1995 Merit Award, University of North Carolina School of Medicine
- 1992 John A. Hartford Foundation Research Fellowship
- 1992 National Institutes of Health Research Fellowship
- 1987-1991 John and Sallie Beard Memorial Scholarship, Duke University
- 1987-1991 Broughton High School Alumni Scholarship

Publications: Author

Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Cheng Y, Campochiaro PA. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 2016;123:330-6.

Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, **Clark L**, Abdelfattah NS, Sadda SR, T-REX AMD Study Group. Prospective trial of treat and extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 2015;122:2514-22.

Patterson M, Bergstrom CS, **Clark WL**, Grossniklaus HE, Payne JF. Severe panuveitis, retinal vasculitis, and optic disk granuloma secondary to sarcoidosis. Retin Cases Brief Rep 2015; epub ahead of print.

Campochiaro PA, **Clark WL**, Boyer DS, Heier JS, Brown DM, Vitti WR, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Zhu X, Haller JA. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 2015;122:538-44.

Geloneck MM, Chuang AZ, **Clark WL**, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA, for the BEAT-ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment. A randomized clinical trial. JAMA Ophthalmol 132:1327-33.

Heier JS, **Clark WL**, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 2014; 121:1414-1420.

Brown DM, Heier JS, **Clark WL**, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phased 3 COPERNICUS study. Am J Ophthalmol 2012;119:1024-32.

Boyer D, Heier J, Brown D, **Clark WL**, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X, Beckman K, Haller JA. VEGF Trap-Eye for macular edema secondary to central retinal vein occlusion: 6-month results of the phase 3 COPERNICUS study. Ophthalmology 2012;119:1024-32.

Zaldivar, RA, Michaels ME, Grant K, **Clark WL**, Grossniklaus HE. Metastatic breast carcinoma to the vitreous. Retina 2004;24:226-30.

Sullivan P, **Clark WL**, Kaiser PK. Bilateral endogenous endophthalmitis caused by HACEK microorganism. Am J Ophthalmol 2002;133:144-5.

Clark WL, Kaiser PK, Flynn HW Jr., Belfort A, Miller D, Meisler DM. Treatment strategies and visual outcomes in chronic postoperative *Propionibacterium acnes* endophthalmitis. Ophthalmology 1999;106:1665-1670.

Clark, WL, Scott IU, Murray TG, Rosa Jr. RH, Siatkowski RM, Langham MR. Primary intraocular post-transplant lymphoproliferative disorder. Arch Ophthalmol 1998;116:1667-1669.

Krol BJ, Murad S, Walker LC, Marshall MK, **Clark WL**, Pinnell SR, Yeowell HN. The expression of a functional, secreted lysyl hydroxylase in a baculovirus system. J Invest Dermatol 1996;106:11-16.

Clark WL, Peiffer RL. Cellular and tissue response to intraocular lenses. Progress in Veterinary and Comparative Ophthalmology 1995;5:50-59.

Yeowell HN, Ha V, **Clark WL**, Marshall MK, Pinnell SR. Sequence analysis of a cDNA for lysyl hydroxylase isolated from human skin fibroblasts from a normal donor: differences from human placental lysyl hydroxylase cDNA. J Invest Dermatol 1994;102:382-384.

Author: Study group

Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; **SCORE Investigator Group**. Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE study report 15. JAMA Ophthalmol 2015;133:1022-9.

Aiello LP, Ayala AR, Antoszyk AN, Arnold-Bush B, Baker C, Bressler NM, Elman MJ, Glassman AR, Jampol LM, Melia M, Nielsen J, Wolpert HA; **Diabetic Retinopathy Clinical Research Network Investigators**. Assessing the effect of personalized diabetes

risk assessments during ophthalmologic visits on glycemic control: a randomized clinical trial. JAMA Ophthalmol 2015;133:888-96.

Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M; **Diabetic Retinopathy Clinical Research Network Investigators**. Repeated intravitreal ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 2015;133:589-97.

Altaweel MM, Daniel E, Martin DF, Mitra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL 3rd, Fine SL, Maguire MG; **Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group**. Outcomes of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatment trials. Ophthalmology 2015;122:391-98.

Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; **Comparison of Age-related Macular Degeneration Treatments Trial (CATT) Research Group**. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatment trials (CATT). JAMA Ophthalmol 2014;132:521-7.

Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG; **Diabetic Retinopathy Clinical Research Network**. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol 2013;131:1033-40.

Busbee BH, Ho AC, Brown DM, Heier JS, Suner IJ, Rubio RG, Lai P; **HARBOR Study Group**. Twelve-month efficacy and safety of 0.5mg or 2.0mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046-56.

Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; **Comparison of AMD Treatments Trial Research Group**. Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatment trials (CATT). Ophthalmology 2013;120:593-99.

Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF; **Comparison of Age-related Macular Degeneration Treatments Trial**. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122-9.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL. Ranibizumab and bevacizumab for neovascular age-related macular degeneration: two year results. Ophthalmology 2012;119:1388-98.

Gangaputra S, Alumkhtar T, Glassman AR, Aiello LP, Bressler N, Bressler SB, Danis RP, Davis MD; **Diabetic Retinopathy Clinical Research Network**. Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus. Invest Ophthalmol Vis Sci 2011;52:6168-73.

The **CATT Research Group**, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908

Mintz-Hittner HA, Kennedy KA, Chuang AZ; **BEAT-ROP Cooperative Group**. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-615.

Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.

Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG; **BRAVO Investigators**. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-1112.

Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; **CRUISE Investigators**. Ranibizumab for macular edema following central retinal vein occlusion: six month primary end point results of a phase III study. Ophthalmology 2010;117:1124-1133.

Diabetic Retinopathy Clinical Research Network Writing Committee, Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, Browning DJ, Danis RP, Glassman AR, Googe JM, Kollman C, Lauer AK, Peters MA, Stockman ME. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010;117:1087-1093.

Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH; **SCORE Study Research Group**. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard of care to treat vision loss associated with macular edema secondary to central retinal vein occlusion; the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1101-1114.

Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzales VH, Singerman LJ, Tolentino M; **SCORE Study Research Group**. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with

standard of care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion; the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1115-1128.

Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN; **SCORE Study Investigator** Group. SCORE study report 7: incidence of intravitreal silicone oil droplets associated with staken-on vs luer cone syringe design. Am J Ophthalmol 2009;148:725-732.

Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, Wells JA 3rd. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol 2009;127:132-140.

Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, **ANCHOR Study Group**. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.

Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H, **Diabetic Retinopathy Clinical Research Network**. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology 2008;115:1366-71.

Diabetic Retinopathy Clinical Research Network, Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year follow up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127:245-51.

Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-9,1449.e1-10.

Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Am J Ophthalmol 2007;114:1860-7.

Writing Committee for the **Diabetic Retinopathy Clinical Research Network**, Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, Danis RP, Davis MD, Feman SS, Ferris F, Friedman SM, Garcia CA, Glassman AR, Han DP, Le D, Kollman C, Laurer AK, Recchia FM, Solomon SD. Comparison of the modified early treatment diabetic retinopathy study and mild macular laser grid photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007; 125: 469-80.

Diabetic Retinopathy Clinical Research Network, Danis RP, Glassman AR, Aiello LP, Antoszyk AK, Beck RW, Browning DJ, Ciardella AP, Kinyoun JL, Murtha TJ, Topping TM, Shami M, Sharuk GS, Wells JA 3rd. Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. Arch Ophthalmol 2006;124:1701-7.

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, for the **ANCHOR Study Group**. Ranibizumab versus Verteporfin for age-related macular degeneration. N Engl J Med 2006;355:1432-44.

Presentations

Clark WL, Abraham P, Brown D, Faber D, Marcus D. Evaluation of long-term treatment with intravitreal aflibercept injection (IAI) in patients completing the VIEW 1 and VIEW extension studies: one-year results of the RANGE study. The Retina Society 48th Annual Scientific Meeting. Paris, France, October 9, 2015.

Clark WL, Brown D, Stemper B. Intravitreal aflibercept for macular oedema due to branch retinal vein occlusion. European Association for Vision and Research Annual Meeting. Nice, France, October 4, 2014

Clark WL. Early visual acuity improvements in RVO patients treated with ranibizumab in SHORE trial. The Retina Society 47th Annual Scientific Meeting. Philadelphia, Pennsylvania, September 14, 2014

Clark WL. Un nueva perspectiva en el manejo de la patologia macular. Sociedad Argentina de Oftalmologia Curso Annual. Buenos Aires, Argentina, August 1, 2014.

Clark WL. Surgical displacement of submacular hemorrhage with tissue-plasminogen activator. In *Macula, presente y futuro*. Sociedad Argentina de Oftalmologia Curso Annual. Buenos Aires, Argentina, August 1, 2014

Clark WL. Long-term safety of intravitreal aflibercept injection in neovascular AMD. American Academy of Ophthalmology Annual Meeting. New Orleans, Louisiana, November 16, 2013.

Clark WL. Intravitreal aflibercept for macular edema due to branch retinal vein occlusion: 24-month results of the VIBRANT study. Retina 2013: Let the Good Times Roll. American Academy of Ophthalmology Annual Meeting Subspecialty Day. New Orleans, Louisiana, November 13, 2013.

Clark WL. Factors affecting the frequency of intravitreal aflibercept injections (IAI) during the PRN phase of the COPERNICUS and GALILEO central retinal vein occlusion (CRVO) studies. The Retina Society 46th Annual Scientific Meeting. Beverly Hills, California, September 27, 2013

Clark WL, Ehrlich JS. Intravitreal ranibizumab modifies the natural history of diabetic retinopathy: 36-month data from the RISE and RIDE phase III trials. American Society of Retinal Specialists 31st Annual Meeting. Toronto, Canada, August 27, 2013

Clark WL. Retina Update 2013. Kiawah Eye 2013. Kiawah Island, South Carolina, May 31, 2013.

Clark WL. Two-year results of the COPERNICUS study evaluating intravitreal aflibercept injection (IAI) for macular edema secondary to central retinal vein occlusion (CRVO). Association for Research and Vision in Ophthalmology 2013 Annual Meeting. Seattle, Washington, May 8, 2013.

Boyer D, Holz F, Brown D, Heier J, Haller J, **Clark WL**, Ogura Y, Korobelnik J-F, Simader C, Roider J. Intravitreal Aflibercept injection (IAI) for macular edema secondary to central retinal vein occlusion (CRVO): results of COPERNICUS 2-year and GALILEO 10-month. 36th Annual Macula Society Meeting 2013. Dana Point, California.

Clark WL, Heier J, Boyer D, Stemper B, Vitti R, for the COPERNICUS Study Group. Intravitreal VEGF trap-eye in central retinal vein occlusion: results of the phase 3 COPERNICUS study. The 8th International Symposium of Ophthalmology, Hong Kong, December 16, 2012.

Boyer DS, Haller JA, Brown DM, Heier JS, **Clark WL**, Vitti R, Berliner AJ, Zeitz O, Groetzbach. 1-year results of the phase 3 COPERNICUS study: intravitreal aflibercept injection in CRVO. Macula Society 2012, Jersalem, Israel.

Clark WL. Retina Update 2012. Kiawah Eye 2012. Kiawah Island, South Carolina, June 1, 2012.

Brown DM, Haller JA, Boyer DS, Heier JS, **Clark WL**, Vitti R, Berliner AJ, Zeitz O, Groetzbach G. Intravitreal aflibercept injection in central retinal vein occlusion: 1-year results of the phase 3 COPERNICUS study. Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, Florida, May 5, 2012.

Haller JA, Boyer DS, Brown DM, Heier JS, **Clark WL**, Vitti R, Berliner AJ. VEGF Trap-Eye in Central Retinal Vein Occlusion: One-Year Results of the Phase 3 COPERNICUS Study. American Academy of Ophthalmology, Orlando, Florida, October 24, 2011.

Clark WL. VEGF Trap Eye for Retinal Vein Occlusion: Copernicus and Galileo. American Academy of Ophthalmology Subspecialty Day, Retina 2011: The Magical World of Retina. Orlando, Florida, October 21, 2011.

Clark WL, Do D, Heier J, Vitti R, Berliner A. VEGF Trap-Eye in Diabetic Macular Edema: One-year Results of the DAVINCI Study. 44th Annual Scientific Session of The Retina Society. Rome, Italy, September 22, 2011.

Boyer DS, Haller J, Brown D, Heier J, **Clark WL**, Vitti R, Berliner A. VEGF Trap-eye in Central Retinal Vein Occlusion: Results from the Phase 3 COPERNICUS Study. 44th Annual Scientific Session of the The Retina Society. Rome, Italy, September 22, 2011.

Clark WL. VEGF Trap-Eye in CRVO: 1-year results of the Phase III COPERNICUS Trial. 29th Annual Meeting, American Society of Retinal Specialists. Boston, Massachusetts, August 22, 2011.

Clark WL. The Future of Diabetic Macular Edema Therapy: Do We Still Need a Laser? Kiawah Eye 2011. Kiawah Island, South Carolina, June 4, 2011.

Clark WL. Future Directions in AMD Management. Kiawah Eye 2011. Kiawah, South Carolina, June 4, 2011.

Haller JA, Boyer DS, Heier JS, Brown DM, **Clark WL**, Vitti R. VEGF Trap-Eye in CRVO: Primary Endpoint Results of the Phase III COPERNICUS Study. Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, Florida, May 03, 2011.

Clark WL. Intravitreal Steroids: Indications and Results. Kiawah Eye 2010. Kiawah Island, South Carolina, May 14, 2010.

Clark WL. Risk Factor Analysis for Visual Acuity and OCT Outcomes Following Vitrectomy for Diabetic Macular Edema in the DRCR Network. American Academy of Ophthalmology, San Francisco, California, October 25, 2009.

Clark WL. Future Directions in Retinopathy of Prematurity Management. Kiawah Eye 2009. Kiawah Island, South Carolina, May 28, 2009.

Clark WL. Emerging Therapies for Age-Related Macular Degeneration. Storm Eye/American Society of Cataract and Refractive Surgery Clinical Update. Kiawah Island, South Carolina, May 29, 2008.

Wroblewski JJ, Wells III JA, Gonzales CR, **Clark WL**, Schwartz SD. Pegaptanib for the treatment of macular edema secondary to branch retinal vein occlusion: interim results of an open label study. 25th Annual Meeting, American Society of Retinal Specialists, Indian Wells, California, December 3, 2007.

Clark WL. Anti-VEGF Therapy for Retinal Diseases. Storm Eye/American Society of Cataract and Refractive Surgery Clinical Update. Kiawah Island, South Carolina, May 29, 2007.

Clark WL. Anti-VEGF Therapy for Age-Related Macular Degeneration. Greenwood Medical Society. Greenwood, South Carolina, October 17, 2006.

Clark WL, Yoser S, Bowie E. Retina Update. American Society of Cataract and Refractive Surgery/Storm Eye Institute Clinical Update 2006. Kiawah Island, South Carolina, June 1, 2006.

Clark WL. Anti-VEGF Therapy: A New Era in AMD Management and Symposium on AMD and VEGF. Reuniao Cientifica, Servico de Oftalmologia do Hospital de S. Joao/F.M.P. Porto, Portugal, September 16, 2005

Clark WL. Photodynamic Therapy: Mono and Combination Therapies. Retina Techs of the Carolinas Meeting, Columbia, South Carolina, August 20, 2005

Wells JA, **Clark WL,** Wroblewski JJ. Inferior displacement of submacular hemorrhage. XXIII Meeting of the Club Jules Gonin, Lausanne, Switzerland, September 2002.

Clark WL, Lewis H. Macular hole after limited macular translocation in patients with previous photocoagulation. Annual Residents and Alumni Day, Cole Eye Institute, The Cleveland Clinic Foundation, Cleveland, Ohio, June 9, 2000.

Clark WL. Introduction to photodynamic therapy. Photodynamic Therapy of Age-Related Macular Degeneration: A Complete Training Course. Cole Eye Institute, The Cleveland Clinic Foundation, Cleveland, OH, June 3, 2000.

Clark WL, Flynn HW Jr., Kaiser PK, Belfort A, Miller D. Intravitreal dexamethasone in the treatment of acute-onset postoperative endophthalmitis. Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, Florida, May, 2000. 35th Annual Residents' Days, Bascom Palmer Eye Institute, Coral Gables, FL, June 18, 1999.

Ysasaga JE, **Clark WL,** Aaberg TM Jr., Rubsamens P, Cousins S. Pediatric ocular trauma. 35th Annual Residents' Days, Bascom Palmer Eye Institute, Coral Gables, FL, June 18, 1999.

Curtin VT, **Clark WL,** Rosa RH Jr. Post organ transplantation lymphoproliferative lesion of iris. Eastern Ophthalmic Pathology Society. Sanibel-Captiva Islands, FL, October 22-25, 1998.

Clark WL, Flynn HW Jr., Belfort A, Miller D, Kaiser PK. Treatment strategies and visual outcomes in chronic postoperative *Propionibacterium acnes* endophthalmitis. Annual Meeting, American Academy of Ophthalmology, New Orleans, LA, November 8, 1998. 34th Annual Residents' Days, Bascom Palmer Eye Institute, Coral Gables, FL, June 12, 1998. Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, May 19, 1998.

Ysasaga JE, **Clark WL**, Aaberg TM Jr., Rubsamén P, Cousins S. Risk factors for poor visual outcome in pediatric penetrating trauma. 34th Annual Residents' Days, Bascom Palmer Eye Institute, Coral Gables, FL, June 12, 1998.

Kaiser PK, **Clark WL**, Meisler D, Flynn HW Jr. Management controversies in *Propionibacterium acnes* endophthalmitis. Cleveland Clinic Division of Ophthalmology Annual Residents and Alumni Meeting, Cleveland, OH, June 12, 1998.

Aaberg TM Jr., **Clark WL**, Rubsamén P. Penetrating and perforating injuries in pediatric patients. Aspen Retinal Detachment Society, Aspen, CO, March 2-3, 1998.

Clark WL, Kaiser PK, Miller D, Flynn HW Jr. Causative organisms and antibiotic sensitivities of culture positive endophthalmitis. 33rd Annual Residents' Days, Bascom Palmer Eye Institute, Coral Gables, FL, June 1997. Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, May 16, 1997.

Clark WL, Pinnell SR, Yeowell HN. Sequence analysis of a full length cDNA for lysyl hydroxylase isolated from human skin fibroblasts. American Geriatric Society/American Federation for Aging Research National Meeting, Washington, DC, November 17, 1993.

Textbook Chapters

Clark WL, Kaiser PK, Flynn HW Jr. Postoperative Endophthalmitis. In eMedicine Ophthalmology. Ed. By James P. Gills, Brian C. Mulrooney, Rober H. Osher, J. James Rowsey, eMedicine.com.

Trattler W and **Clark WL**. Granular Dystrophy. In eMedicine Ophthalmology. Ed. By James P. Gills, Brian C. Mulrooney, Rober H. Osher, J. James Rowsey, eMedicine.com.

Trattler W and **Clark WL**. Lattice Dystrophy. In eMedicine Ophthalmology. Ed. By James P. Gills, Brian C. Mulrooney, Rober H. Osher, J. James Rowsey, eMedicine.com.

Clark WL, Callejo SA, Rosa RH Jr. Anatomy, embryology, and pathology of the crystalline lens. In Bascom Palmer Eye Institute's Atlas of Ophthalmology. Ed. by Richard K Parrish II, Current Medicine.

Non-peer-reviewed Publications

Clark WL. Surgical options for the back of the eye. Advanced Ocular Care 2011.

Clark WL. Intravitreal steroids for cystoid macular edema. Advanced Ocular Care 2010.

Scott IU, **Clark WL**, Fantes F, Kay M, Lewis ML, Siatkowski RM. Grand rounds: patient with diabetes has sudden visual loss in left eye. Ophthalmology Times 1997; 22:26-28.

Clinical Research: Principal Investigator

- 2017-present:** A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with geographic atrophy secondary to Age-Related Macular Degeneration who have completed a Roche-sponsored study-Genentech OMASPECT-GX30191
- 2016-present** A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy- Regeneron VGFTe-OD-1411 (Panorama)
- 2016-present** A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration- Genentech GX28228-(LADDER)
- 2016-2017** A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Diabetic Macular Edema-Regeneron 1518
- 2015-2017** A Multiple-Center, Multiple-Dose And Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36-Week Study To Investigate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Ro6867461 Administered Intravitreally In Patients With Choroidal Neovascularization Secondary To Age-Related Macular Degeneration- Genentech Avenue-BP29647
- 2014-2017** Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance Trial 2).
- 2015-2017** A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration. Regeneron R2176-3-AMD-1417
- 2014-2015** Evaluation of Abicipar Pegol (AGN-150998) in Patients with Decreased Vision Due to Diabetic Macular Edema- Allergan 150998-004
- 2014-2017** A Phase III, Multicenter, Randomized, Double-Masked, Sham - Controlled Study To Assess The Efficacy And Safety of Lampalizumab Administered Intravitreally To Patients with Geographic Atrophy Secondary To Age-Related Macular Degeneration-Genentech GX29185 Spectri

- 2014-2016** An Open-Label, Dose-Escalation Study Of The Safety And Tolerability of Intravitreal (Ivt) Regn910-3 and IVT REGN910 in Patients with either Neovascular AMD or DME-Regeneron 1403
- 2013-2015** 5 year follow up: Study of COmparative Treatments for REtinal Vein Occlusion 2 A multicenter, prospective, randomized non-inferiority trial of eyes with Macular Edema secondary to Central Retinal Vein Occlusion, comparing intravitreal Bevacizumab every 4 weeks with intravitreal Aflibercept every 4 weeks SCORE 2
- 2013-2015:** Treat and extend therapy study using intravitreal aflibercept for patients exited from protocol VGFT-OD 0910 (RANGE)
- 2013-2017:** A phase IIIb, multicenter, randomized, controlled study of the safety, tolerability and efficacy of intravitreal injections of 0.5mg ranibizumab given monthly compared to a Treat and Extend protocol in patients with wet age-related macular degeneration (TREX AMD).
- 2012-2016:** An open-label study of the efficacy, safety, and tolerability of intravitreal administration of VEGF Trap-Eye (intravitreal Aflibercept injection) in patients with neovascular age-related macular degeneration-Regeneron 1124
- 2012-2014:** A multicenter, open-label, randomized study comparing the efficacy and safety of 700ug dexamethasone posterior segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema- Allergan 206207-024
- 2012-2014:** A double-masked, randomized, active-controlled study of the efficacy, safety, and tolerability of intravitreal administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI] in patients with macular edema secondary to branch retinal vein occlusion Regeneron 1027 BRVO
- 2012-2013** Phase 2 Multi-Center, Randomized, Double Masked, Placebo-Controlled, Multi-Dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of RN6G (Pf-04382923) In Subjects With Geographic Atrophy Secondary To Age-Related Macular Degeneration- Pfizer B1181003
- 2011-2015:** A double-masked, randomized, active-controlled, phase 3 study of the efficacy and safety of intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema- Regeneron 1009
- 2011-2016:** A phase III, multinational, multicenter, randomized, double-masked, study assessing the safety and efficacy of intravitreal injections of DE-109 (three

doses) for the treatment of active, non-infectious uveitis of the posterior segment of the eye-Santen

- 2011-2012:** A multi-center randomized study evaluating dosing regimens for treatment with intravitreal ranibizumab injections in subjects with macular edema following Retinal Vein Occlusion
- 2011-2012:** A phase IB/II, multicenter, randomized, single-masked, sham injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month to patients with Geographic Atrophy
- 2010-2012:** DNA repository substudy in association with ranibizumab study FVF4579g: a phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5mg and 2.0mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration
- 2010:** VEGF Trap-Eye pharmacokinetic sub-study VGFT-OD-0706.PK
- 2010-2012:** A phase I, double-masked, placebo-controlled study evaluating the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple escalating dosages of RN6G in subjects with advanced dry, age-related macular degeneration (AMD) including geographic atrophy
- 2009-2012:** A phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5mg and 2.0mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration
- 2009-2011:** A randomized, double masked, controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in Subjects with macular edema secondary to central retinal vein occlusion (CRVO)
- 2009-2011:** A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema (DME)
- 2008-2010:** A phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of Sirolimus in patients with diabetic macular edema secondary to diabetic retinopathy

- 2008-2011:** Intravitreal bevacizumab (Avastin™) injections versus conventional laser for vision-threatening retinopathy of prematurity: a prospective, randomized, non-blinded, controlled, multi-center trial
- 2008-2009:** A phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion
- 2007-2010:** Intravitreal ranibizumab or triamcinolone acetonide in combination to laser photocoagulation for diabetic macular edema
- 2007-2009:** Intravitreal ranibizumab or triamcinolone acetonide as adjunctive treatment to panretinal photocoagulation for proliferative diabetic retinopathy
- 2007-2011:** A randomized, double-masked, active-controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF trap in subjects with neovascular age-related macular degeneration
- 2007-2011:** A phase III, double-masked, multi-center randomized, sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus (RISE and RIDE)
- 2007-2009:** A 24-month randomized, double masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with ranibizumab (Lucentis™) versus ranibizumab (Lucentis™) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
- 2007-2008:** DNA repository study in association with study FVF3426g (An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who have completed the treatment phase of a Genentech sponsored ranibizumab study)
- 2006-2007:** A phase 2 evaluation of anti-VEGF therapy for diabetic macular edema: Bevacizumab (Avastin)
- 2006-2007:** Clinical evaluation of the safety of next generation ophthalmic irrigating solution (NGOIS) compared to BSS Plus for use during surgery for removal of epimacular membrane with vitrectomy

- 2006:** A retrospective medical chart review of neovascular age-related macular degeneration (AMD) subjects treated with Macugen monotherapy
- 2005-2008:** A Phase IIIB, single-masked, multicenter, randomized study to evaluate the safety and tolerability of Ranibizumab in naive and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
- 2005-2008:** A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin (Visudyne®) plus two different dose regimens of intravitreal triamcinolone acetonide (1mg and 4mg) versus Visudyne® plus intravitreal pegaptanib (Macugen®) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
- 2005-2008:** Diabetic Retinopathy Clinical Research Network: Evaluation of vitrectomy for diabetic macular edema study
- 2005-2007:** An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who have completed the treatment phase of a Genentech sponsored ranibizumab study
- 2004-2008:** A six-month phase III, multicenter, masked, randomized, sham-controlled trial (with six-month open-label extension) to assess the safety and efficacy of 700 µg and 350µg dexamethasone posterior segment drug delivery system (DEX PS DDS Applicator System) in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion
- 2004-2008:** Diabetic Retinopathy Clinical Research Network Protocol II: A randomized trial comparing intravitreal corticosteroids and laser photocoagulation for diabetic macular edema
- 2003-2006:** Diabetic Retinopathy Clinical Research Network Protocol 1-A: A pilot study of laser photocoagulation for diabetic macular edema
- 2003-2006:** A phase III, multicenter, randomized, double-masked, active treatment-controlled study of the efficacy and safety of rhuFab (ranibizumab) compared with Verteporfin (Visudyne®) photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration
- 2001-2006:** A randomized, controlled study on the efficacy and safety of Sandostatin LAR in the therapy of patients with moderately severe or severe non-

proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy (PDR)

Clinical Research: Investigator

- 2017-present** A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura® (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration- Ophthotech OPH2003
- 2017-present** A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease- Ophthotech OPH2005
- 2017-present** A dose-ranging study of intravitreal OPT-302 in combination with Ranibizumab, compared with Ranibizumab alone, in participants with Neovascular Age-Related Macular Degeneration (wet AMD)-Opthea OPT 302-1002
- 2017-present** Phase 1b/2a study of OPT-302 in combination with Aflibercept for persistent Central-Involvement Diabetic Macular Edema-Opthea OPT 302-1003
- 2016-present** A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 28-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of ro6867461 administered intravitreally in patients with Diabetic Macular Edema- Genentech Boulevard-BP30099
- 2014-2017** An Open label, Single Ascending Dose Study to Investigate the Safety, Efficacy and Pharmacodynamics of a Novel Plasma Kallikrein Inhibitor Administered by Intravitreal Injection in Subjects with Central Involved Diabetic Macular Edema and Reduced Vision. KalVista
- 2014-2016** A Phase 1 Open-Label, Multi-Center Trial with Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD) Pan Optica-PAN-01-101
- 2016-2017** A Phase 1/2a Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in combination with Ranibizumab in subjects with wet AMD. Opthea- OPT-302-1001

- 2015-2016** A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hIcon1™ in Patients with Choroidal Neovascularization Secondary to Age related Macular Degeneration. Iconic Protocol Number: IT-002
- 2015-2017** A Multicenter, Prospective Epidemiologic Study of the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Genentech GX29639- Proxima B
- 2015-2017** A Multicenter, Prospective Epidemiologic Study of the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Genentech GX29633- Proxima A
- 2013-2016:** A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti-PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration. Ophthotech OPH1003
- 2013-present:** A phase II, multicenter, randomized, controlled study of the safety, tolerability and efficacy of intravitreal injections of 0.3 mg ranibizumab given monthly compared to a Treat and Extend protocol in patients with Diabetic Macular Edema (T-REX-DME)
- 2012-2015** Multi-Center Randomized, Single Masked Phase 2 Study of Intravitreal Injections of SIROLIMUS in the Treatment of Central Geographic Atrophy associated with Age- Related Macular Degeneration
- 2012-2016** Diabetic Retinopathy Clinical Research Network: A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema. Protocol T
- 2011-2016** A Phase 2a, Multi-center , Masked, Randomized, Comparator-controlled Study Evaluating iSONEP(Sonepcizumab LT 1009) as Either Monotherapy or Adjunctive Therapy to Lucentis or Avastin Versus Lucentis or Avastin Alone for the treatment of Subjects with Choroidal Neovascularization Secondary to Age-related Macular Degeneration- LPath
- 2011-present** Diabetic Retinopathy Clinical Research Network: Genes in Diabetic Retinopathy Project
- 2011-2015** Diabetic Retinopathy Clinical Research Network: Effect of Diabetes Education during Retinal Ophthalmology Visits on Diabetes Control

- 2011-2013:** A Multi-Center Randomized, Sham-controlled, Repeat –Dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG 316 in Patients with Neovascular Age-Related macular degeneration-Novartis LFG316A
- 2011-2012:** A phase 1/2 trial to investigate the safety and tolerability of single and repeated doses of hI-CON™ following administration by intravitreal injection in subjects with neovascular age-related macular degeneration
- 2010-2012:** A phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration
- 2009-2012:** The safety and efficacy of AL-8309B ophthalmic solution for the treatment of geographic atrophy secondary to age-related macular degeneration
- 2008-2010:** An open-label, long-term, safety, and tolerability study of intravitreal VEGF Trap-EYE in subjects with neovascular age-related macular degeneration
- 2008-2009:** The natural history of geographic atrophy progression (GAP) secondary to age-related macular degeneration
- 2008-2011:** Comparison of age-related macular degeneration treatment trials (CATT)
- 2007-2009:** A phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered 8 or 12 weeks as maintenance therapy following three injections of Lucentis® compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration
- 2007-2010:** A phase II multicenter, randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in subjects with age-related macular degeneration
- 2007-2008:** A trial to assess the safety and tolerability of repeated doses of intravitreal administration of two VEGF trap formulations in subjects with neovascular age related macular degeneration
- 2007-2009:** A randomized placebo controlled efficacy and safety study of one year treatment duration with high and medium dose inhaled Mometasone Furoate/Formoterol combination formulation compared to Formoterol and

high dose inhaled Mometasone Furoate monotherapy in subjects with severe COPD: P04229 and P04230

- 2007-2013:** Age-related Eye Diseases Study 2 (AREDS2): A multi-center, randomized trial of lutein, zeaxanthin, and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in age-related macular degeneration

- 2006-2008:** A phase IV, open label, multi-center trial of maintenance intravitreal injections of Macugen® (Pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration initially treated with a modality resulting in maculopathy improvement

- 2006-2008:** Open label Macugen for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO)

- 2006-2007:** A phase II, pharmacokinetic, randomized, double-masked, controlled, dose comparison study of Cand5 for intravitreal injection for the treatment of diabetic macular edema

- 2005-2007:** Diabetic Retinopathy Clinical Research Network: An observational study of the development of diabetic macular edema following scatter laser photocoagulation

- 2005-2007:** A phase 2/3 randomized, controlled, double-masked, multi-center, comparative dose-finding trial, in parallel groups, to compare the safety and efficacy of intravitreal injections of 0.3, 0.03, or 0.003 mg pegaptanib sodium (Macugen®), given as often as every 6 weeks for 3 years, to sham injections, in subjects with diabetic macular edema (DME) involving the center of the macula

- 2005:** Temporal variation in optical coherence tomography measurements of retinal thickening in diabetic macular edema

- 2004-2006:** A Phase 1/2, randomized, masked, placebo-controlled, single and multiple-dose, sequential dose-escalation study of the safety and efficacy of AG-013958 in subjects with subfoveal choroidal neovascularization associated with age-related macular degeneration

- 2004-2005:** An open label, non-comparative protocol for the use of pegaptanib sodium injection every 6 weeks in patients with exudative age-related macular degeneration

- 2004-2005:** A Phase II randomized, double-masked, multi-center trial, in parallel groups, to compare the safety, efficacy, and pharmacokinetics of

intravitreal injections of pegaptanib sodium to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to CRVO

- 2004-2005:** A Phase II prospective, randomized, double-masked, dose-ranging, multi-center trial to assess the effect of pegaptanib sodium on macular thickening measured by OCT in patients with exudative subfoveal age-related macular degeneration
- 2004-2008:** The standard care vs. corticosteroid for retinal vein occlusion. The SCORE study
- 2004-2008:** An evaluation of efficacy and safety of posterior juxtасleral administrations of anecortave acetate for depot suspension (15 mg or 30 mg) versus sham administration in patients (enrolled in Study “A” or Study “B”) at risk for developing sight-threatening choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD)
- 2003-2004:** An open-label, multi-center trial of the safety, tolerability and pharmacokinetics of 3 mg/eye intravitreal injections of pegaptanib sodium (Anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD)
- 2002-2004:** A phase II randomized, controlled, double-masked, dose-finding, multi-center, comparative trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (Anti-VEGF pegylated aptamer), given every 6 weeks for 12 to 30 weeks to patients with clinically significant diabetic macular edema (CSME) involving the center of the macula
- 2001-2006:** A phase II/III randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD)

Protocol Steering Committee

- 2012-present Protocol Steering Committee, SAKURA DE-109, Santen Pharmaceuticals, Inc.
- 2012-present Protocol Steering Committee, VGTFe-RVO-1027, Regeneron Pharmaceuticals, Inc.
- 2009-present Central Retinal Vein Occlusion Steering Committee, Regeneron Pharmaceuticals, Inc.
- 2007-2009 Diabetic Retinopathy Clinical Research Network Intravitreal Triamcinolone (Protocol B) Steering Committee

Editorial Board

2009-present Advanced Ocular Care

Journal Manuscript Reviewer

2011-present European Journal of Ophthalmology

2002-present Ophthalmology

Hospital Appointments

2003-2004 Chief, Department of Ophthalmology
Palmetto Baptist Medical Center
Columbia, South Carolina

Other Appointments

2010-2013 President, Carolina Aquatics Swim Club, Inc.

2007-2009 Board of Directors, South Carolina Chapter, Reading for the Blind and
Dyslexic

2006-present Chairman, Thomas Pitts Eye Fund

Professional Organizations

2014-present European Association for Vision and Eye Research

2013-present The Retina Society

2012-present Club Vit

2004-present Columbia Medical Society

2003-present American Society of Retinal Specialists

2001-present South Carolina Ophthalmological Society

2000-present Central South Carolina Ophthalmological Society

2000-present South Carolina Medical Society

1999-present Bascom Palmer Eye Institute Alumni Association

1998-present American Academy of Ophthalmology

1998-present American Society of Cataract and Refractive Surgery

1996-present Association for Research in Vision and Ophthalmology

1995-present University of North Carolina Medical Alumni Association